Warwick Company UK Limited
Total Consideration
$158.0M
2 years of history · ending 2025-12-31 · SEC EDGAR
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | — | — | — | — | — | — |
| State & Local Income Taxes | — | — | — | — | — | — |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | — | — | 0.20% |
| Effective Tax Rate | 10.90% | 12.20% | 7.20% | -13.90% | 19.70% | 17.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $45.0M | $58.0M | $11.0M | −$93.0M | $96.0M | $119.0M |
| Income Taxes Paid (Cash) | −$25.0M | $24.0M | $105.0M | $4.0M | $90.0M | $51.0M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$158.0M
Per-case litigation disclosures sourced from us-gaap:LossContingenciesByNatureOfContingencyAxis dimensional XBRL. Coverage is sparse — most filers aggregate at the parent level (JNJ talc, PFE opioid) — but high-value when per-case disclosure exists. Loss estimate is either a single point or a low/high range, depending on how the issuer values the contingency.
As of 2023-06-26
| Case | Estimated Loss | Damages Sought | Settlement |
|---|---|---|---|
| Guarantee Obligations | — | $8.50B | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).